Literature DB >> 25710037

An expedient synthesis, acetylcholinesterase inhibitory activity, and molecular modeling study of highly functionalized hexahydro-1,6-naphthyridines.

Abdulrahman I Almansour1, Raju Suresh Kumar1, Natarajan Arumugam1, Alireza Basiri2, Yalda Kia3, Mohamed Ashraf Ali4.   

Abstract

A series of class="Chemical">hexahydro-1,6-naphthyridines were synthesized in good yields by the reaction of class="Chemical">pan class="Chemical">3,5-bis[(E)-arylmethylidene]tetrahydro-4(1H)-pyridinones with cyanoacetamide in the presence of sodium ethoxide under simple mixing at ambient temperature for 6-10 minutes and were assayed for their acetylcholinesterase (AChE) inhibitory activity using colorimetric Ellman's method. Compound 4e with methoxy substituent at ortho-position of the phenyl rings displayed the maximum inhibitory activity with IC50 value of 2.12 μM. Molecular modeling simulation of 4e was performed using three-dimensional structure of Torpedo californica AChE (TcAChE) enzyme to disclose binding interaction and orientation of this molecule into the active site gorge of the receptor.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 25710037      PMCID: PMC4325472          DOI: 10.1155/2015/965987

Source DB:  PubMed          Journal:  Biomed Res Int            Impact factor:   3.411


1. Introduction

class="Disease">Alzheimer's disease (class="Chemical">pan class="Disease">AD) is associated with loss of cholinergic neurons in basal forebrain, which results in loss or failure of memory which slowly worsens and eventually incapacitates the patients [1, 2]. According to the World Alzheimer report, AD is one among the most significant social, health, and economic crises of the 21st century [3]. Although the exact factors initiating AD are unclear, genetic and environmental factors have been implicated [4]. In general, pharmacological therapies have twin objectives: (i) to prevent the loss of the neurons and (ii) to restore the cholinergic functions of AD patients. Cholinesterase inhibitors have been used clinically for symptomatic treatment of AD [5]. Acetylcholinesterase (AChE) enzyme is involved in the breakdown of acetylcholine in the brain and inhibition of this enzyme may increase the efficacy of treatment and broaden the indications [6]. Effects of cholinesterase inhibitors are mainly due to enhancement of cholinergic transmission at cholinergic autonomic synapses and at the neuromuscular junction [7]. class="Gene">AChE inhibitors are one of the most actively investigated classes of comclass="Chemical">pounds in the search for an effective treatment of class="Chemical">pan class="Disease">AD. Although there are many ongoing research activities in the search of drugs for treating AD, only few drugs like galantamine, donepezil, and rivastigmine are now available [8], and these drugs do not show potential cure rates; additional treatments are still being developed. The treatment of AD still remains an area of significant unmet need, with drugs that only target the symptoms of the disease. Therefore, there is considerable need for disease-modifying therapies. To meet the need of disease-modifying drugs for AD, in recent years, new approaches have emerged in medicinal chemistry. In particular the concept has recently been proposed that due to the multifactorial and complex etiology of AD, the modulation of a single factor might not be sufficient to produce the desired efficacy. Researchers are now paying attention to the design of structures that could be able to simultaneously interact with different targets involved in the pathogenic process [9, 10]. class="Chemical">Naphthyridine structural motif has been extensively synthesized and incorclass="Chemical">porated into biologically active molecules [11]. In class="Chemical">particular, class="Chemical">pan class="Chemical">1,6-naphthyridines exhibit a broad spectrum of biological activities such as being inhibitor of HIV-1 integrase [12, 13], HCMV [14, 15], FGF receptor-1 tyrosine kinase [16], and the enzyme acetylcholinesterase [17]. Many routes for the syntheses of 1,6-naphthyridines derivatives have previously been reported [18-21]. In continuation of our previous work towards the synthesis of novel hybrid heterocycles employing new synthetic methodologies and/or their potential as inhibitors of AChE [22-26], herein we report the synthesis and AChE inhibitory activities of nitrogen heterocyclic hybrids comprising naphthyridine structural motif.

2. Materials and Methods

2.1. Chemistry

General Methods. Melting points were measured in KRUSS melting point meter using open capillary tubes and are uncorrected. class="Chemical">1H and class="Chemical">pan class="Chemical">13C NMR spectra were recorded on a Bruker 300 MHz instrument in DMSO using TMS as internal standard. Standard Bruker software was used throughout. Chemical shifts are given in parts per million (δ-scale) and the coupling constants are given in Hertz. IR spectra were recorded in a Perkin Elmer system 2000 FT IR instrument (KBr). Elemental analyses were performed on a Perkin Elmer 2400 Series II Elemental CHNS analyser. Mass spectra were recorded in Agilent technologies 7820A GC-MS system.

2.1.1. General Procedure for the Synthesis of Naphthyridines (4a–k)

A mixture of class="Chemical">3,5-bis[(E)-arylmethylidene]tetrahydro-4(1H)-pyridinones (1 mmol) and class="Chemical">pan class="Chemical">2-cyanoacetamide (1 mmol) in ethanol (200 μL) in the presence of catalytic amount of sodium ethoxide (5 mg) were ground well in a semimicro boiling tube at ambient temperature for about 6–10 min. After completion of the reaction as evident from TLC, water (50 mL) was added to the reaction mixture and the product was filtered, washed with water, and dried in vacuo. class="Chemical">(E)-8-Benzylidene-2-oxo-4-phenyl-1,2,5,6,7,8-hexahydro-1,6-naphthyridine-3-carbonitrile ( ). Pale yellow solid; IR (KBr) ν max⁡ 3372, 2945, 2213, 1642, 1625 cm−1; class="Chemical">pan class="Chemical">1H NMR (300 MHz, DMSO): δ H 3.15 (d, J = 15.9 Hz, 1H, 5-CH2), 3.35 (d, J = 15.9 Hz, 1H, 5-CH2), 3.60 (d, J = 15.6 Hz, 1H, 7-CH2), 3.69 (d, J = 15.6 Hz, 1H, 7-CH2), 7.07–7.38 (m, 10H, Ar-H), 7.81 (s, 1H, Arylmethylidene-H), 8.15 (s, 1H, NH). 13C NMR (75 MHz, DMSO): δ C 45.48, 45.76, 79.31, 101.70, 115.22, 116.94, 126.21, 127.81, 128.84, 129.50, 130.78, 131.10, 134.71, 135.54, 137.90, 146.85, 159.18, 162.83. EIMS: m/z 341 [M+1]. Anal. calcd for C22H17N3O: C, 77.86; H, 5.05; N, 12.38; found: C, 77.69; H, 5.22; N, 12.25%. (E)-8-(2-Methylbenzylidene)-2-oxo-4-(o-tolyl)-1,2,5,6,7,8-hexahydro-class="Chemical">1,6-naphthyridine-3-carbonitrile ( ). Yellow solid; IR (KBr) ν max⁡ 3380, 2948, 2210, 1640, 1627 cm−1; class="Chemical">pan class="Chemical">1H NMR (300 MHz, DMSO): δ H 2.13 (s, 3H, CH3), 2.30 (s, 3H, CH3), 3.14 (d, J = 15.9 Hz, 1H, 5-CH2), 3.33 (d, J = 15.9 Hz, 1H, 5-CH2), 3.62 (d, J = 15.6 Hz, 1H, 7-CH2), 3.68 (d, J = 15.6 Hz, 1H, 7-CH2), 7.04–7.35 (m, 8H, Ar-H), 7.80 (s, 1H, Arylmethylidene-H), 8.14 (s, 1H, NH). 13C NMR (75 MHz, DMSO): δ C 19.75, 20.56, 45.43, 45.82, 79.76, 101.32, 115.23, 116.91, 126.21, 127.03, 127.79, 128.89, 129.33, 129.53, 129.92, 130.78, 131.19, 134.76, 135.42, 135.55, 137.91, 146.96, 159.08, 162.92. EIMS: m/z 369 [M+1]. Anal. calcd for C24H21N3O: C, 78.45; H, 5.76; N, 11.44; found: C, 78.32; H, 5.98; N, 11.29%. (E)-8-(2-class="Chemical">Chlorobenzylidene)-4-(2-class="Chemical">pan class="Chemical">chlorophenyl)-2-oxo-1,2,5,6,7,8-hexahydro-1,6-naphthyridine-3-carbonitrile ( ). Pale yellow solid; IR (KBr) ν max⁡ 3384, 2950, 2214, 1642, 1625 cm−1; 1H NMR (300 MHz, DMSO): δ H 3.16 (d, J = 15.6 Hz, 1H, 5-CH2), 3.34 (d, J = 15.6 Hz, 1H, 5-CH2), 3.61 (d, J = 15.6 Hz, 1H, 7-CH2), 3.68 (d, J = 15.6 Hz, 1H, 7-CH2), 7.10–7.36 (m, 8H, Ar-H), 7.81 (s, 1H, Arylmethylidene-H), 8.12 (s, 1H, NH). 13C NMR (75 MHz, DMSO): δ C 45.38, 45.95, 79.70, 101.64, 115.21, 116.90, 126.28, 127.01, 127.85, 128.90, 129.31, 129.54, 129.93, 130.69, 131.26, 134.73, 135.40, 135.52, 137.90, 146.91, 159.13, 162.90. EIMS: m/z 408 [M+1]. Anal. calcd for C22H15Cl2N3O: C, 64.72; H, 3.70; N, 10.29; found: C, 64.80; H, 3.87; N, 10.48%. (E)-8-(2-Bromobenzylidene)-4-(2-bromophenyl)-2-oxo-1,2,5,6,7,8-hexahydro-class="Chemical">1,6-naphthyridine-3-carbonitrile ( ). Pale yellow solid; IR (KBr) ν max⁡ 3381, 2950, 2210, 1644, 1626 cm−1; class="Chemical">pan class="Chemical">1H NMR (300 MHz, DMSO): δ H 3.18 (d, J = 15.9 Hz, 1H, 5-CH2), 3.34 (d, J = 15.9 Hz, 1H, 5-CH2), 3.62 (d, J = 15.9 Hz, 1H, 7-CH2), 3.69 (d, J = 15.6 Hz, 1H, 7-CH2), 7.16–7.39 (m, 8H, Ar-H), 7.82 (s, 1H, Arylmethylidene-H), 8.09 (s, 1H, NH). 13C NMR (75 MHz, DMSO): δ C 44.93, 45.80, 79.78, 101.61, 115.20, 116.96, 126.25, 127.05, 127.81, 128.98, 129.35, 129.62, 129.92, 130.73, 131.24, 134.71, 135.43, 135.51, 137.93, 146.90, 159.17, 162.92. EIMS: m/z 498 [M+1]. Anal. calcd for C22H15Br2N3O: C, 53.15; H, 3.04; N, 8.45; found: C, 53.38; H, 3.16; N, 8.37%. (E)-8-(2-Methoxybenzylidene)-4-(2-methoxyphenyl)-2-oxo-1,2,5,6,7,8-hexahydro-class="Chemical">1,6-naphthyridine-3-carbonitrile ( ). Yellow solid; IR (KBr) ν max⁡ 3385, 2944, 2210, 1641, 1627 cm−1; class="Chemical">pan class="Chemical">1H NMR (300 MHz, DMSO): δ H 3.14 (d, J = 15.6 Hz, 1H, 5-CH2), 3.31 (d, J = 15.6 Hz, 1H, 5-CH2), 3.60 (d, J = 15.6 Hz, 1H, 7-CH2), 3.68 (d, J = 15.6 Hz, 1H, 7-CH2), 3.74 (s, 3H, OCH3), 3.82 (s, 3H, OCH3), 7.11–7.38 (m, 8H, Ar-H), 7.83 (s, 1H, Arylmethylidene-H), 8.10 (s, 1H, NH). 13C NMR (75 MHz, DMSO): δ C 45.39, 45.93, 55.51, 55.70, 79.70, 101.67, 114.20, 114.81, 115.20, 116.94, 126.31, 127.81, 128.93, 129.56, 130.66, 131.29, 134.70, 135.42, 137.90, 146.95, 159.07, 159.14, 160.04, 162.95. EIMS: m/z 401 [M+1]. Anal. calcd for C24H21N3O3: C, 72.16; H, 5.30; N, 10.52; found: C, 72.30; H, 5.53; N, 10.39%. (E)-8-(2,4-Diclass="Chemical">chlorobenzylidene)-4-(2,4-diclass="Chemical">pan class="Chemical">chlorophenyl)-2-oxo-1,2,5,6,7,8-hexahydro-1,6-naphthyridine-3-carbonitrile ( ). Pale yellow solid; IR (KBr) ν max⁡ 3380, 2951, 2219, 1646, 1628 cm−1; 1H NMR (300 MHz, DMSO): δ H 3.18 (d, J = 15.9 Hz, 1H, 5-CH2), 3.37 (d, J = 15.9 Hz, 1H, 5-CH2), 3.60 (d, J = 15.6 Hz, 1H, 7-CH2), 3.68 (d, J = 15.6 Hz, 1H, 7-CH2), 7.14–7.42 (m, 6H, Ar-H), 7.82 (s, 1H, Arylmethylidene-H), 8.09 (s, 1H, NH). 13C NMR (75 MHz, DMSO): δ C 45.35, 45.97, 79.65, 101.62, 115.26, 116.81, 126.30, 127.12, 127.87, 128.94, 129.43, 129.60, 129.94, 130.74, 131.27, 134.72, 135.47, 135.53, 137.94, 146.97, 159.16, 162.95. EIMS: m/z 478 [M+1]. Anal. calcd for C22H13Cl4N3O: C, 55.38; H, 2.75; N, 8.81; found: C, 55.29; H, 2.92; N, 8.70%. (E)-8-(3-Nitrobenzylidene)-4-(3-nitrophenyl)-2-oxo-1,2,5,6,7,8-hexahydro-pan class="Chemical">1,6-naphthyridine-3-carbonitrile ( ). Yellow solid; IR (KBr) ν max⁡ 3389, 2942, 2210, 1645, 1626 cm−1; class="Chemical">pan class="Chemical">1H NMR (300 MHz, DMSO): δ H 3.21 (d, J = 15.9 Hz, 1H, 5-CH2), 3.39 (d, J = 15.9 Hz, 1H, 5-CH2), 3.61 (d, J = 15.6 Hz, 1H, 7-CH2), 3.70 (d, J = 15.6 Hz, 1H, 7-CH2), 7.12–7.38 (m, 8H, Ar-H), 7.80 (s, 1H, Arylmethylidene-H), 8.11 (s, 1H, NH). 13C NMR (75 MHz, DMSO): δ C 45.32, 45.95, 79.66, 101.60, 115.24, 116.79, 126.31, 127.15, 127.86, 128.93, 129.41, 129.64, 129.96, 130.75, 131.30, 134.71, 135.49, 135.61, 137.92, 146.95, 159.14, 162.93. EIMS: m/z 431 [M+1]. Anal. calcd for C22H15N5O5: C, 61.54; H, 3.52; N, 16.31; found: C, 61.27; H, 3.75; N, 16.18%. (E)-8-(4-Methylbenzylidene)-2-oxo-4-(p-tolyl)-1,2,5,6,7,8-hexahydro-class="Chemical">1,6-naphthyridine-3-carbonitrile ( ). Pale yellow solid; IR (KBr) ν max⁡ 3387, 2940, 2212, 1647, 1625 cm−1; class="Chemical">pan class="Chemical">1H NMR (300 MHz, DMSO): δ H 2.25 (s, 3H, CH3), 2.29 (s, 3H, CH3), 3.20 (d, J = 15.9 Hz, 1H, 5-CH2), 3.41 (d, J = 15.9 Hz, 1H, 5-CH2), 3.63 (d, J = 15.6 Hz, 1H, 7-CH2), 3.72 (d, J = 15.6 Hz, 1H, 7-CH2), 7.12–7.40 (m, 8H, Ar-H), 7.83 (s, 1H, Arylmethylidene-H), 8.12 (s, 1H, NH). 13C NMR (75 MHz, DMSO): δ C 21.4, 21.8, 45.35, 45.97, 79.68, 101.64, 115.25, 116.80, 126.32, 127.18, 127.82, 128.91, 129.45, 129.96, 130.69, 131.35, 134.73, 135.47, 135.64, 137.90, 139.21, 146.94, 159.17, 162.90. EIMS: m/z 369 [M+1]. Anal. calcd for C24H21N3O: C, 78.45; H, 5.76; N, 11.44; found: C, 78.66; H, 5.87; N, 11.35%. (E)-8-(4-class="Chemical">Chlorobenzylidene)-4-(4-class="Chemical">pan class="Chemical">chlorophenyl)-2-oxo-1,2,5,6,7,8-hexahydro-1,6-naphthyridine-3-carbonitrile ( ). Yellow solid; IR (KBr) ν max⁡ 3385, 2942, 2210, 1645, 1627 cm−1; 1H NMR (300 MHz, DMSO): δ H 3.17 (d, J = 15.9 Hz, 1H, 5-CH2), 3.40 (d, J = 15.9 Hz, 1H, 5-CH2), 3.62 (d, J = 15.6 Hz, 1H, 7-CH2), 3.71 (d, J = 15.6 Hz, 1H, 7-CH2), 7.16–7.48 (m, 8H, Ar-H), 7.87 (s, 1H, Arylmethylidene-H), 8.15 (s, 1H, NH). 13C NMR (75 MHz, DMSO): δ C 45.39, 45.94, 79.70, 101.65, 115.26, 116.81, 126.34, 127.21, 127.85, 128.94, 129.48, 129.91, 130.76, 131.39, 134.71, 135.51, 135.60, 137.90, 146.92, 159.25, 162.97. EIMS: m/z 409 [M+1]. Anal. calcd for C22H15Cl2N3O: C, 64.72; H, 3.70; N, 10.29; found: C, 64.95; H, 3.84; N, 10.21%. (E)-8-(4-Fluorobenzylidene)-4-(4-fluorophenyl)-2-oxo-1,2,5,6,7,8-hexahydro-class="Chemical">1,6-naphthyridine-3-carbonitrile ( ). Pale yellow solid; IR (KBr) ν max⁡ 3387, 2940, 2213, 1645, 1624 cm−1; class="Chemical">pan class="Chemical">1H NMR (300 MHz, DMSO): δ H 3.15 (d, J = 15.9 Hz, 1H, 5-CH2), 3.37 (d, J = 15.9 Hz, 1H, 5-CH2), 3.63 (d, J = 15.6 Hz, 1H, 7-CH2), 3.70 (d, J = 15.9 Hz, 1H, 7-CH2), 7.13–7.45 (m, 8H, Ar-H), 7.84 (s, 1H, Arylmethylidene-H), 8.11 (s, 1H, NH). 13C NMR (75 MHz, DMSO): δ C 45.37, 45.93, 79.72, 101.64, 114.36, 114.58, 115.23, 116.85, 126.37, 127.84, 128.92, 129.45, 130.72, 131.35, 134.78, 135.43, 137.94, 146.96, 159.25, 160.23, 161.18, 162.95. EIMS: m/z 377 [M+1]. Anal. calcd for C22H15F2N3O: C, 70.39; H, 4.03; N, 11.19; found: C, 70.65; H, 4.27; N, 11.10%. (E)-4-(Naphthalen-1-yl)-8-(naphthalen-1-ylmethylene)-2-oxo-1,2,5,6,7,8-hexahydro-class="Chemical">1,6-naphthyridine-3-carbonitrile ( ). Pale yellow solid; IR (KBr) ν max⁡ 3384, 2946, 2214, 1645, 1629 cm−1; class="Chemical">pan class="Chemical">1H NMR (300 MHz, DMSO): δ H 3.17 (d, J = 15.9 Hz, 1H, 5-CH2), 3.41 (d, J = 15.9 Hz, 1H, 5-CH2), 3.61 (d, J = 15.6 Hz, 1H, 7-CH2), 3.70 (d, J = 15.6 Hz, 1H, 7-CH2), 7.02–7.65 (m, 14H, Ar-H), 7.91 (s, 1H, Arylmethylidene-H), 8.17 (s, 1H, NH). 13C NMR (75 MHz, DMSO): δ C 45.31, 45.84, 79.68, 101.65, 115.28, 116.80, 123.46, 124.03, 125.12, 125.57, 126.30, 126.42, 126.80, 127.20, 127.85, 128.22, 129.12, 129.48, 129.94, 130.79, 131.43, 132.10, 132.67, 134.73, 135.54, 135.68, 137.92, 146.90, 159.28, 162.94. EIMS: m/z 441 [M+1]. Anal. calcd for C30H21N3O: C, 81.98; H, 4.82; N, 9.56; found: C, 81.80; H, 4.95; N, 9.48%.

2.2. In Vitro Cholinesterase Enzymes Inhibitory Assay

class="Gene">Cholinesterase inhibitory activity of the synthesized comclass="Chemical">pounds was evaluated using the Ellman's microclass="Chemical">plate assay [27]. For class="Chemical">pan class="Gene">acetylcholinesterase (AChE) inhibitory assay, 140 μL of 0.1 M sodium phosphate buffer (pH 8) was first added to a 96-well microplate followed by 20 μL of test samples and 20 μL of 0.09 units/mL acetylcholinesterase enzyme from Electrophoruselectricus (Sigma). After 15 minutes of incubation at 25°C, 10 μL of 10 mM 5,5′-dithiobis-2-nitrobenzoic acid (DTNB) was added into each well followed by 10 μL of acetylthiocholine iodide (14 mM). At 30 minutes after the initiation of enzymatic reaction, absorbance of the colored end-product was measured using BioTek Power Wave X 340 Microplate Spectrophotometer at 412 nm. class="Chemical">Galantamine was used as class="Chemical">positive control. Test samclass="Chemical">ples and class="Chemical">pan class="Chemical">galantamine were prepared in DMSO at an initial concentration of 1 mg/mL (1000 ppm). The concentration of DMSO in final reaction mixture was 1%. At this concentration, DMSO has no inhibitory effect on acetylcholinesterase enzyme. The initial screening was carried out at 10 μg/mL of test samples in 1% pan class="Chemical">DMSO and each test was conducted in triclass="Chemical">plicate. Absorbencies of the test samclass="Chemical">ples were corrected by subtracting the absorbance of their resclass="Chemical">pective blank. Percentage enzyme inhibition is calculated using the following formula: Subsequently, the determination of IC50 was carried out using a set of five concentrations.

2.3. Molecular Modeling

Using Glide (version 5.7, Schrödinger, LLC, New York, NY, 2011), most active compound was docked onto the active site of Tcclass="Gene">AChE derived from three-dimensional structure of the enzyme comclass="Chemical">plex with anti-class="Chemical">pan class="Disease">Alzheimer's drug, galantamine (PDB ID: 4EVE). pan class="Chemical">Water molecules and hetero grouclass="Chemical">ps were deleted from enzyme beyond the rclass="Chemical">pan class="Disease">adius of 5 Å of reference ligand (galantamine), resulting protein structure refined and minimized by Protein Preparation Wizard using OPLS-2005 force field. Receptor Grid Generation program was used to prepare TcAChE grid and the ligand was optimized by LigPrep program by using OPLS-2005 force field to generate lowest energy state. Docking stimulations were carried out on bioactive compound, handed in 5 poses per ligand, in which the best pose with highest score was displayed for each ligand.

3. Results and Discussion

3.1. Chemistry

In the present investigation, the reaction of a series of class="Chemical">bisarylmethylidene piperidones with class="Chemical">pan class="Chemical">2-cyanoacetamide in the presence of sodium ethoxide with few drops of ethanol under simple mixing at ambient temperature for 6–10 min afforded functionalized 1,6-naphthyridines in good yields (65–78%; Scheme 1). The prerequisite bisarylmethylidene piperidones were synthesized following the literature reported method [28]. In a typical reaction, an equimolar mixture of 3,5-bis[(E)-2-methylphenylmethylidene]tetrahydro-4(1H)-pyridinones (2b) and 2-cyanoacetamide (3) in catalytic amount of sodium ethoxide were ground well in a semimicro boiling tube with few drops of ethanol at ambient temperature for about 7 min and after completion of the reaction water was added to the mixture and the product was filtered and dried in vacuo. In this case, the 2-pyridone was obtained as a sole reaction product and does not require column chromatography for purification. Easy availability of the reagents, short reaction time, and simple reaction condition rendered this method more attractive from the viewpoint of green chemistry.
Scheme 1

Synthesis of naphthyridines (4a–k).

The structure of class="Chemical">1,6-naphthyridines was elucidated using IR, NMR, and CHN analysis. In the class="Chemical">pan class="Chemical">1H NMR spectrum of 4b, the two doublets at 3.14 and 3.33 ppm with J = 15.9 Hz are due to 5-CH2 protons while the other doublets at 3.62 and 3.68 ppm with J = 15.6 Hz are due to 7-CH2 protons of the piperidine ring. The singlets at 8.14 and 7.80 ppm can be attributed to the NH of 2-pyridone ring and arylmethylidene proton, respectively. The two –CH3 protons of aromatic ring appear as singlets at 2.13 and 2.30 ppm while the multiplets around 7.04–7.35 ppm are due to aromatic protons. In the 13C NMR spectrum, the chemical shifts at 19.75 and 20.56 ppm were due to the two –CH3 carbons whilst the two methylene carbons of the piperidine ring resonated at 45.43 and 45.82 ppm. The aromatic carbons resonated at 101.32–162.92 ppm. The molecular ion peak at 369 [M+1] confirms the presence of compound 4b. The elemental analysis result of 4b was within ±0.4% of the theoretical values. The structure of other 2-pyridones was also assigned by similar considerations. Presumably, the 1,6-naphthyridine (4) is formed via a cascade heterocyclization mechanism involving an initial Michael addition followed by cyclization and air oxidation as reported by Jain et al. [29].

3.2. In Vitro Evaluation

All newly synthesized pan class="Chemical">1,6-naphthyridines were evaluated in vitro for their inhibitory class="Chemical">potential against class="Chemical">pan class="Gene">AChE enzyme from electric eel using colorimetric Ellman's method (Table 1). All the 1,6-naphthyridines (4a–k) displayed good to moderate inhibitory activities with IC50 values ranging from 2.12 to 24.72 μM, irrespective of the position of the substituent on the aryl ring. Among the 1,6-naphthyridines, compounds 4i with p-chloro, 4k with 1-naphthyl, 4h with p-methyl, and 4b with o-methyl substituent in the aromatic ring displayed good activities (<10 μM) with IC50 3.86 μM, 6.86 μM, 7.16 μM, and 7.20 μM, respectively. Compounds 4a, 4c, 4d, 4g, and 4j displayed moderate activities (IC50 = 11.18–18.16 μM) while compound 4f displayed the lowest activity (IC50 = 24.72 μM). Compound 4e with o-methoxy phenyl rings displayed the highest activity with IC50 value of 2.12 μM, comparable to the standard drug galantamine (IC50 = 2.09 μM). It is also observed that the AChE inhibitory activities were directly correlated to the size of substituents in the phenyl ring. For instance, derivative bearing bulky moieties, such as m-nitro, o,p-dichloro, and p-bromo, displayed lower inhibition than the derivatives carrying smaller functions irrespective of their position in the phenyl ring.
Table 1

Physical data and AChE inhibitory activity of naphthyridines (4a–k).

EntryProductReaction time (min)Yield(%)mp °CAChE inhibition(IC50  ± SD) mol/L
1 875211-21211.18 ± 0.02

2 772229-2307.20 ± 0.02

3 776220-22115.21 ± 0.1

4 670208-20918.16 ± 0.02

5 967215-2162.12 ± 0.02

6 672225-22624.72 ± 0.01

7 670206-20716.86 ± 0.02

8 773235-2367.16 ± 0.02

9 678221-2223.86 ± 0.02

10 774218-21914.16 ± 0.02

11 1065204-2056.86 ± 0.02

12Galantamine.HBr2.09 ± 0.02
The active site of pan class="Gene">AChE enzyme is located inside a 20 Å long, narrow gorge which is dominantly comclass="Chemical">posed of amino acids class="Chemical">possessing aromatic side chains such as class="Chemical">pan class="Chemical">tryptophan and tyrosine. Therefore, the derivatives bearing a relatively small and/or electron donating moieties in phenyl rings, such as methyl and methoxy, displayed better inhibitory activities than derivatives carrying bulky and/or electron withdrawing groups, plausibly due to the better insertion into the active site channel and also more efficient binding interaction with aforementioned aromatic residues. However with limited substituent on the aryl ring, it is difficult to ascertain the exact structure activity relationship based on their activities observed.

3.3. Docking Studies

The most active class="Gene">AChE inhibitor, 4e, was docked into the active site of class="Chemical">pan class="Gene">AChE enzyme derived from crystal structure of Torpedo californica AChE (TcAChE). The docking analysis revealed that this compound is properly inserted into the active site of AChE enzyme with free binding energy of 8.71 kcal/mol and strongly bound to the residues comprising aromatic side chains such as Tyr70 (H-bonding 1.16 Å), Tyr121 (hydrophobic), Tyr334 (hydrophobic) at peripheral anionic site as well as Phe330 (hydrophobic), and Trp84 (π,π-stacking) at choline binding site of the enzyme (Figure 1). 4e also exhibited mild polar interaction with Gly116 and Gly117 at oxyanion hole of the AChE enzyme. The crystal structure of the TcAChE in complex with available AD drugs such as galantamine and huperzine A showed similar interactions with residues composing peripheral anionic site along with stacking against Trp84 at bottom of the gorge. It seems that the presence of methoxy group in 4e has notable influence on proper positioning of this compound in AChE active site. This orientation effectively avoids insertion and hydrolysis of substrate inside the AChE active site channel and completely coincides with the activity observed for this compound.
Figure 1

Binding interaction of 4e with active site of AChE receptor. (Hydrogen atoms are not shown for clarity.)

4. Conclusion

A series of novel class="Chemical">1,6-naphthyridines were synthesized in good yields and evaluated for their inhibitory class="Chemical">potentials against class="Chemical">pan class="Gene">AChE enzyme, using colorimetric Ellman's method. Among them, compound 4e displayed the highest AChE inhibition with remarkable IC50 value of 2.12 μM, comparable to standard drug, galantamine. Molecular modeling analysis for this compound manifested its orientation inside the active site cavity and its effective binding interactions to the residues lining the active site channel, which coincided with its in vitro activity.
  21 in total

Review 1.  Designed multiple ligands. An emerging drug discovery paradigm.

Authors:  Richard Morphy; Zoran Rankovic
Journal:  J Med Chem       Date:  2005-10-20       Impact factor: 7.446

2.  Acetylcholinesterase inhibitors for Alzheimer's disease: anti-inflammatories in acetylcholine clothing!

Authors:  N Tabet
Journal:  Age Ageing       Date:  2006-07       Impact factor: 10.668

3.  A potent and orally active HIV-1 integrase inhibitor.

Authors:  Melissa S Egbertson; H Marie Moritz; Jeffrey Y Melamed; Wei Han; Debra S Perlow; Michelle S Kuo; Mark Embrey; Joseph P Vacca; Matthew M Zrada; Amanda R Cortes; Audrey Wallace; Yvonne Leonard; Daria J Hazuda; Michael D Miller; Peter J Felock; Kara A Stillmock; Marc V Witmer; William Schleif; Lori J Gabryelski; Gregory Moyer; Joan D Ellis; Lixia Jin; Wei Xu; Matthew P Braun; Kellem Kassahun; Nancy N Tsou; Steven D Young
Journal:  Bioorg Med Chem Lett       Date:  2006-12-03       Impact factor: 2.823

Review 4.  Multi-target-directed ligands to combat neurodegenerative diseases.

Authors:  Andrea Cavalli; Maria Laura Bolognesi; Anna Minarini; Michela Rosini; Vincenzo Tumiatti; Maurizio Recanatini; Carlo Melchiorre
Journal:  J Med Chem       Date:  2008-01-09       Impact factor: 7.446

Review 5.  Alzheimer's disease is not "brain aging": neuropathological, genetic, and epidemiological human studies.

Authors:  Peter T Nelson; Elizabeth Head; Frederick A Schmitt; Paulina R Davis; Janna H Neltner; Gregory A Jicha; Erin L Abner; Charles D Smith; Linda J Van Eldik; Richard J Kryscio; Stephen W Scheff
Journal:  Acta Neuropathol       Date:  2011-04-24       Impact factor: 17.088

6.  An expedient synthesis and screening for antiacetylcholinesterase activity of piperidine embedded novel pentacyclic cage compounds.

Authors:  Raju Suresh Kumar; Abdulrahman I Almansour; Natarajan Arumugam; Hasnah Osman; Mohamed Ashraf Ali; Alireza Basiri; Yalda Kia
Journal:  Med Chem       Date:  2014-03       Impact factor: 2.745

7.  An expedient, ionic liquid mediated multi-component synthesis of novel piperidone grafted cholinesterase enzymes inhibitors and their molecular modeling study.

Authors:  Alireza Basiri; Vikneswaran Murugaiyah; Hasnah Osman; Raju Suresh Kumar; Yalda Kia; Khalijah Binti Awang; Mohamed Ashraf Ali
Journal:  Eur J Med Chem       Date:  2013-07-04       Impact factor: 6.514

8.  Microwave assisted synthesis, cholinesterase enzymes inhibitory activities and molecular docking studies of new pyridopyrimidine derivatives.

Authors:  Alireza Basiri; Vikneswaran Murugaiyah; Hasnah Osman; Raju Suresh Kumar; Yalda Kia; Mohamed Ashraf Ali
Journal:  Bioorg Med Chem       Date:  2013-04-01       Impact factor: 3.641

9.  Synthesis of 5-(1-H or 1-alkyl-5-oxopyrrolidin-3-yl)-8-hydroxy-[1,6]-naphthyridine-7-carboxamide inhibitors of HIV-1 integrase.

Authors:  Jeffrey Y Melamed; Melissa S Egbertson; Sandor Varga; Joseph P Vacca; Greg Moyer; Lori Gabryelski; Peter J Felock; Kara A Stillmock; Marc V Witmer; William Schleif; Daria J Hazuda; Yvonne Leonard; Lixia Jin; Joan D Ellis; Steven D Young
Journal:  Bioorg Med Chem Lett       Date:  2008-08-14       Impact factor: 2.823

10.  A facile chemo-, regio- and stereoselective synthesis and cholinesterase inhibitory activity of spirooxindole-pyrrolizine-piperidine hybrids.

Authors:  Yalda Kia; Hasnah Osman; Raju Suresh Kumar; Vikneswaran Murugaiyah; Alireza Basiri; Subbu Perumal; Ibrahim Abdul Razak
Journal:  Bioorg Med Chem Lett       Date:  2013-03-23       Impact factor: 2.823

View more
  2 in total

Review 1.  Natural Peptides in Drug Discovery Targeting Acetylcholinesterase.

Authors:  Vivitri Prasasty; Muhammad Radifar; Enade Istyastono
Journal:  Molecules       Date:  2018-09-13       Impact factor: 4.411

2.  Multi Component Reactions under Increased Pressure: On the Mechanism of Formation of Pyridazino[5,4,3-de][1,6]naphthyridine Derivatives by the Reaction of Malononitrile, Aldehydes and 2-Oxoglyoxalarylhydrazones in Q-Tubes.

Authors:  Majdah A Al-Johani; Khadijah M Al-Zaydi; Sameera M Mousally; Norah F Alqahtani; Noha Hilmy Elnagdi; Mohamed H Elnagdi
Journal:  Molecules       Date:  2017-12-01       Impact factor: 4.411

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.